Truist Financial Forecasts Strong Price Appreciation for Quest Diagnostics (NYSE:DGX) Stock

Quest Diagnostics (NYSE:DGX) had its price target raised by stock analysts at Truist Financial from $225.00 to $250.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the medical research company’s stock. Truist Financial’s price objective would suggest a potential upside of 8.49% from the stock’s previous close.

A number of other analysts have also weighed in on DGX. UBS Group reiterated a “neutral” rating and set a $232.00 target price on shares of Quest Diagnostics in a report on Friday. Weiss Ratings raised Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, July 9th. Barclays raised their price target on Quest Diagnostics from $230.00 to $250.00 and gave the stock an “overweight” rating in a research note on Thursday. Robert W. Baird lifted their price target on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a report on Friday. Finally, Wall Street Zen lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Monday. Six equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $229.45.

Quest Diagnostics Trading Up 1.1%

DGX stock traded up $2.54 during midday trading on Friday, hitting $230.44. The company had a trading volume of 824,071 shares, compared to its average volume of 965,840. The stock has a market cap of $25.51 billion, a price-to-earnings ratio of 25.47, a PEG ratio of 2.50 and a beta of 0.58. Quest Diagnostics has a 52 week low of $165.78 and a 52 week high of $237.78. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.67. The stock’s 50 day moving average price is $202.40 and its 200 day moving average price is $197.37.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same period in the previous year, the firm earned $2.62 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. As a group, equities research analysts expect that Quest Diagnostics will post 10.72 earnings per share for the current fiscal year.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the transaction, the senior vice president owned 13,510 shares in the company, valued at approximately $2,702,000. The trade was a 37.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the sale, the chief executive officer directly owned 132,423 shares in the company, valued at $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Quest Diagnostics

Large investors have recently modified their holdings of the stock. Tema ETFs LLC boosted its holdings in shares of Quest Diagnostics by 10.6% during the 2nd quarter. Tema ETFs LLC now owns 1,518 shares of the medical research company’s stock valued at $322,000 after acquiring an additional 145 shares during the last quarter. Czech National Bank grew its position in Quest Diagnostics by 5.2% in the 2nd quarter. Czech National Bank now owns 31,508 shares of the medical research company’s stock worth $6,678,000 after purchasing an additional 1,550 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab grew its position in Quest Diagnostics by 7.7% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 14,000 shares of the medical research company’s stock worth $2,967,000 after purchasing an additional 1,000 shares during the period. Assenagon Asset Management S.A. raised its stake in Quest Diagnostics by 39.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 15,405 shares of the medical research company’s stock valued at $3,265,000 after buying an additional 4,334 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Quest Diagnostics by 36.3% during the 2nd quarter. GAMMA Investing LLC now owns 5,295 shares of the medical research company’s stock valued at $1,122,000 after buying an additional 1,411 shares during the period. Hedge funds and other institutional investors own 88.06% of the company’s stock.

More Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quest Diagnostics beat Wall Street estimates for Q2, reporting adjusted EPS of $3.12 and revenue of $3.04 billion, both above expectations, with revenue up 10.2% year over year. Article Title
• Positive Sentiment: The company raised its full-year 2026 outlook, now expecting adjusted EPS of $11.05 to $11.25 and revenue of $11.95 billion to $12.05 billion, signaling confidence in continued demand. Article Title
• Positive Sentiment: Management pointed to strong routine and preventive testing demand as a key growth driver, which supports the view that Quest can sustain momentum beyond the quarter. Article Title
• Neutral Sentiment: Robert W. Baird raised its price target to $255 from $236 while keeping a neutral rating, suggesting upside potential but not a full bullish upgrade. Article Title
• Neutral Sentiment: Several momentum-focused articles and “52-week high” commentary may keep trader interest elevated, but these pieces are largely follow-through on the earnings beat rather than new fundamentals. Article Title

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.